NSCLC
![Krazati + Keytruda Slows Down KRASG12C-Mutated NSCLC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Krazati-Keytruda-Slows-Down-KRASG12C-Mutated-NSCLC.jpg)
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-NaĆÆve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
![Keytruda + Chemo Boosts Survival in Resectable NSCLC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/KEYNOTE-671-Trial_-Keytruda-Sets-New-Standards-in-the-Perioperative-Treatment-Landscape.jpg)
KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)
ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merckās Keytruda is ...
![ESMO 2023](https://pharmtales.com/wp-content/uploads/2023/10/Rybrevant-Redefines-First-Line-Care-for-Patients-with-EGFR-Exon-20-Insertion-Mutation.jpg)
Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)
ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...
![Tagrisso leads lung cancer market with $7B sales](https://pharmtales.com/wp-content/uploads/2023/10/AstraZenecas-Tagrisso-dominates-lung-cancer-market-with-projected-7B-sales-by-2025.jpg)
AstraZenecaās Tagrisso dominates lung cancer market with projected $7B sales by 2025
The lung cancer drug market has been notably dominated by antibodies and immunotherapies, but a recent report from GlobalData suggests ...
![Pfizer wins FDA approval for lung cancer combo](https://pharmtales.com/wp-content/uploads/2023/10/Pfizer-gets-FDA-nod-for-Lorbrena-Vizimpro-combo-to-treat-advanced-lung-cancer.jpg)
Pfizer gets FDA nod for Lorbrena-Vizimpro combo to treat advanced lung cancer
Pfizer is making strategic moves to reinforce its presence in the oncology arena, with the FDA granting approval for its ...
![Amgenās Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now](https://pharmtales.com/wp-content/uploads/2023/10/Amgens-Lumakras-flunks-FDA-expert-meeting-but-market-withdrawal-looks-unlikely-for-now.jpg)
Amgenās Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
![FDA Identifies 'Systemic Bias' in Amgen's Late-Stage Lumakras Trial Ahead of Adcomm](https://pharmtales.com/wp-content/uploads/2023/10/FDA-Identifies-Systemic-Bias-in-Amgens-Late-Stage-Lumakras-Trial-Ahead-of-Adcomm.jpg)
FDA Identifies ‘Systemic Bias’ in Amgen’s Late-Stage Lumakras Trial Ahead of Adcomm
As an FDA advisory committee prepares to deliberate on the data supporting Amgen’s groundbreaking drug Lumakras, a pre-meeting briefing document ...
![TROPION-Lung04, datopotamab deruxtecan, Dato-DXd, Imfinzi, NSCLC, International Association for the Study of Lung Cancer, IASLC 2023, Immunotherapy, antibody-drug conjugate](https://pharmtales.com/wp-content/uploads/2023/09/Datopotamab-Deruxtecan-Imfinzi-Transform-First-Line-NSCLC-Treatment-in-TROPION-Lung04-Trial.jpg)
Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial
The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...
![Tecentriq, Roche, Lung Cancer, NSCLC, Alecensa, Clinical trial results, ALK-positive NSCLC](https://pharmtales.com/wp-content/uploads/2023/09/Roches-Alecensa-beats-chemo-in-early-stage-lung-cancer-following-Tecentriqs-lead.jpg)
Rocheās Alecensa beats chemo in early-stage lung cancer, following Tecentriqās lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
![Roche, Lung Cancer, TIGIT, Tecentriq, tiragolumab, Clinical trial results, NSCLC](https://pharmtales.com/wp-content/uploads/2023/08/Roche-Unveils-Interim-TIGIT-Overall-Survival-Data-Following-Unintended-Release-Triggering-Surge-in-Stocks.jpg)
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
![Lumakras, Amgen, KRAS mutation, KRAS inhibitor, KRAS G12C mutation, NSCLC, Krazati](https://pharmtales.com/wp-content/uploads/2023/08/FDA-Convenes-Advisors-to-Assess-Full-Approval-Prospects-for-Amgens-Lumakras-Amid-KRAS-Uncertainties.jpg)
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
![KRASG12C Inhibitors for NSCLC: How Garsorasib Stands Out](https://pharmtales.com/wp-content/uploads/2023/07/Results-from-Garsorasib-Expand-the-Class-of-KRASG12C-Inhibitors-in-NSCLC.jpg)
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced nonāsmall cell lung cancer ...
![Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC](https://pharmtales.com/wp-content/uploads/2023/07/Lazertinib-Beats-Gefitinib-in-Treating-EGFR-Mutated-NSCLC.jpg)
Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC
In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...
![New Combination Therapy Shows Promise for Lung Cancer Patients with Rare Mutation](https://pharmtales.com/wp-content/uploads/2023/07/Positive-Effects-of-Rybrevant-Plus-Chemotherapy-in-Early-EGFR-Exon-20-Insertion-NSCLC.jpg)
Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC
Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...
![FDA states that LN-145 in NSCLC is likely to receive accelerated approval](https://pharmtales.com/wp-content/uploads/2023/07/FDA-states-that-LN-145-in-NSCLC-is-likely-to-receive-accelerated-approval.jpg)
FDA states that LN-145 in NSCLC is likely to receive accelerated approval
Source – Iovance Biotherapeutics The Phase II IOV-LUN-202 trial of LN-145 in patients with post-anti-PD-1 non-small cell lung cancer (NSCLC) ...
![The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising](https://pharmtales.com/wp-content/uploads/2023/07/The-Safety-of-THIO-Sequenced-With-Cemiplimab-in-NSCLC-Remains-Promising.jpg)
The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising
Source – MAIA Biotechnology Two patients with advanced non-small cell lung cancer (NSCLC) have not experienced disease progression for 12.2 ...
![Datopotamab Deruxtecan Meets Dual Primary Endpoint in TROPION-Lung01 Phase III Trial for Advanced Non-Small Cell Lung Cancer - Pharmtales](https://pharmtales.com/wp-content/uploads/2023/07/Datopotamab-Deruxtecan-Meets-Dual-Primary-Endpoint-in-TROPION-Lung01-Phase-III-Trial-for-Advanced-Non-Small-Cell-Lung-Cancer.jpg)
DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...
![Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression - Pharmtales](https://pharmtales.com/wp-content/uploads/2023/07/Pembrolizumab-demonstrate-effectiveness-beyond-five-years-as-a-first-line-treatment-for-advanced-NSCLC-with-PD-L1-expression.jpg)
Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression
First-line treatment with pembrolizumab (Keytruda) has demonstrated long-term survival benefits and durable responses in patients with PD-L1-positive, locally advanced or ...